132 related articles for article (PubMed ID: 11266783)
1. Intracellular signaling consequences of anti-IL-2Ralpha blockade by daclizumab.
Tkaczuk J; Milford E; Yu C; Baksh S; Carpenter C; Burakoff S; McKay D
Transplant Proc; 2001; 33(1-2):212-3. PubMed ID: 11266783
[No Abstract] [Full Text] [Related]
2. Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events.
Goebel J; Stevens E; Forrest K; Roszman TL
Transpl Immunol; 2000 Nov; 8(3):153-9. PubMed ID: 11147695
[TBL] [Abstract][Full Text] [Related]
3. IL-15R alpha-chain expression during anti-CD25 treatment of cardiac allograft recipients.
Baan CC; Balk AH; van der Plas AJ; van Gelder T; Vantrimpont PJ; Maat LP; Weimar W
Transplant Proc; 2002 Dec; 34(8):3243-5. PubMed ID: 12493434
[No Abstract] [Full Text] [Related]
4. Daclizumab: a potential asthma therapy?
Antoniu SA
Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):214-21. PubMed ID: 20804450
[TBL] [Abstract][Full Text] [Related]
5. Window of opportunity for daclizumab.
Schluns KS
Nat Med; 2011 May; 17(5):545-7. PubMed ID: 21546970
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation.
Koch M; Niemeyer G; Patel I; Light S; Nashan B
Transplantation; 2002 May; 73(10):1640-6. PubMed ID: 12042653
[TBL] [Abstract][Full Text] [Related]
7. IL-7 and IL-15 bypass the immunosuppressive action of anti-CD25 monoclonal antibodies.
Baan CC; Boelaars-van Haperen MJ; van Riemsdijk IC; van der Plas AJ; Weimar W
Transplant Proc; 2001 May; 33(3):2244-6. PubMed ID: 11377516
[No Abstract] [Full Text] [Related]
8. Daclizumab rapidly saturates interleukin-2 receptor-alpha (CD25) on lymph node lymphocytes in children.
Savo AM; Book BK; Henson S; Hakimi J; Pescovitz MD
Transplant Proc; 1999; 31(1-2):1182-3. PubMed ID: 10083528
[No Abstract] [Full Text] [Related]
9. Effect of anti-IL-2Ralpha antibody on IL-2-induced Jak/STAT signaling.
Tkaczuk J; Yu CL; Baksh S; Milford EL; Carpenter CB; Burakoff SJ; McKay DB
Am J Transplant; 2002 Jan; 2(1):31-40. PubMed ID: 12095053
[TBL] [Abstract][Full Text] [Related]
10. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade.
ter Meulen CG; Baan CC; Hené RJ; Hilbrands LB; Hoitsma AJ
Transplantation; 2001 Nov; 72(10):1709-10. PubMed ID: 11726840
[No Abstract] [Full Text] [Related]
11. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
12. IL-2 receptor blockade inhibits late, but not early, IFN-gamma and CD40 ligand expression in human T cells: disruption of both IL-12-dependent and -independent pathways of IFN-gamma production.
McDyer JF; Li Z; John S; Yu X; Wu CY; Ragheb JA
J Immunol; 2002 Sep; 169(5):2736-46. PubMed ID: 12193748
[TBL] [Abstract][Full Text] [Related]
13. Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies basiliximab and daclizumab.
Binder M; Vögtle FN; Michelfelder S; Müller F; Illerhaus G; Sundararajan S; Mertelsmann R; Trepel M
Cancer Res; 2007 Apr; 67(8):3518-23. PubMed ID: 17440057
[TBL] [Abstract][Full Text] [Related]
14. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice?
Van Gelder T; Warlé M; Ter Meulen RG
Drugs; 2004; 64(16):1737-41. PubMed ID: 15301558
[TBL] [Abstract][Full Text] [Related]
15. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
Swiatecka-Urban A
Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627
[TBL] [Abstract][Full Text] [Related]
16. A role for interleukin-2 trans-presentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy.
Wuest SC; Edwan JH; Martin JF; Han S; Perry JS; Cartagena CM; Matsuura E; Maric D; Waldmann TA; Bielekova B
Nat Med; 2011 May; 17(5):604-9. PubMed ID: 21532597
[TBL] [Abstract][Full Text] [Related]
17. The effects of interleukin-2 on immune response regulation.
Waters RS; Perry JSA; Han S; Bielekova B; Gedeon T
Math Med Biol; 2018 Mar; 35(1):79-119. PubMed ID: 28339682
[TBL] [Abstract][Full Text] [Related]
18. Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis.
Krueger JG; Walters IB; Miyazawa M; Gilleaudeau P; Hakimi J; Light S; Sherr A; Gottlieb AB
J Am Acad Dermatol; 2000 Sep; 43(3):448-58. PubMed ID: 10954656
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of immunosuppression by the therapeutic antibody daclizumab.
Yang H; Wang J; Du J; Zhong C; Zhang D; Guo H; Guo Y; Ding J
Cell Res; 2010 Dec; 20(12):1361-71. PubMed ID: 20820193
[TBL] [Abstract][Full Text] [Related]
20. The interleukin-2 inhibitors and their role in low-toxicity regimens.
Nashan B
Transplant Proc; 1999 Dec; 31(8A):23S-26S. PubMed ID: 10616557
[No Abstract] [Full Text] [Related]
[Next] [New Search]
